Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will have discussions with (a) Eisai Co., Ltd and Biogen Inc. and (b) Eli Lilly and Company on the production of disease-modifying treatments for Alzheimer's disease in the UK.

The Government deeply values its relationships with life science companies and is committed to getting treatments to National Health Service patients through our 10 Year Plan for the NHS. This will include a plan for procurement, giving a clearer route to getting products into the NHS, coupled with reformed incentive structures to drive innovation and faster regulatory approval for new technology and medicines. The Government engages regularly with companies on the production of disease-modifying treatments for Alzheimer's disease in the United Kingdom, such as those developed by Eisai, Biogen, and Eli Lilly, and where appropriate, ministers may be involved in this engagement.